Elritercept is under clinical development by Keros Therapeutics and currently in Phase II for Anemia. According to GlobalData, Phase II drugs for Anemia have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Elritercept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Elritercept overview

Elritercept (KER-050) is under development for the treatment of cytopenias including anemia and thrombocytopenia in patients with myelodysplastic Syndrome (MDS) and myelofibrosis (MF). It is administered through subcutaneous route. The drug candidate is a protein which is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-beta receptor, activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. 

It was also under development for the treatment of Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD)

Keros Therapeutics overview

Keros Therapeutics is a biopharmaceutical company that discovers, develops and commercializes novel treatments for hematological and musculoskeletal disorders. The company’s product pipeline includes KER-050 for the treatment of low blood cell counts and cytopenias, including anemia and thrombocytopenia for patients with myelodysplastic syndrome (MDS) and myelofibrosis (MF); KER-047 for treating functional iron deficiency (FID) anemia in MDS and myelofibrosis (MF). Its pipeline also includes KER-012 to treat pulmonary arterial hypertension and chronic heart failure with preserved ejection fraction; and KER-065 to treat Duchenne muscular dystrophy. The company is developing other drug programs that are at a pre-clinical stage in areas of musculoskeletal disorders. Keros Therapeutics is headquartered in Lexington, Massachusetts, the US.

For a complete picture of Elritercept’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.